Moderna announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use, or CHMP, has adopted a positive opinion recommending marketing authorization for Spikevax, its updated COVID-19 vaccine containing spike proteins for the XBB.1.5 sublineage of SARS-CoV-2 for active immunization to prevent COVID-19 caused by SARS-CoV-2 in individuals six months of age and older. Following the CHMP’s positive opinion, the European Commission will make an authorization decision on the use of Moderna’s updated COVID-19 vaccine for autumn/winter 2023, the company stated.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on MRNA:
- Moderna (NASDAQ:MRNA) Surges after Landing EU Approval
- Market seems ‘only focused on Covid’ for Moderna, says Jefferies
- Moderna sees combo flu/COVID vaccine available as early as 2025
- Moderna up after forecasting up to $15B in sales by 2027 from respiratory drugs
- Moderna price target lowered to $140 from $160 at Argus